Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Drug Dose Mode Days Rituximab: 375 mg/m 2: IV infusion: Day 1 Ifosfamide: 5000 mg/m 2: IV continuous infusion over 24 hours: Day 2 Mesna for haemorrhagic cystitis prophylaxis with ifosfamide: 5000 mg/m 2: IV continuous infusion over 24 hours: Day 2 Carboplatin: Optimized to get AUC = 5 (max. 800 mg) IV infusion: Day 2 Etoposide: 100 mg/m 2: IV ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Indications [1] [2] [4] Major toxicities [1] [2] [4] [5] 1. Cytotoxic antineoplastics: 1.01 Nucleoside analogues: Azacitidine: SC, IV: DNA methyltransferase inhibitor and incorporates itself into RNA, hence inhibiting gene expression. [6] Myelodysplastic syndromes, acute myeloid leukaemia and chronic myeloid leukaemia
R-miniCHOP is indicated in elderly patients (>80 years) with diffuse large B-cell lymphoma due to less toxicity from the reduced dose in comparison to R-CHOP.. R-Maxi-CHOP is used in mantle cell lymphoma and is given in 21-day intervals, alternating with R-HDAC (rituximab + high-dose cytarabine).
Drug Manufacturer Indication Adagrasib: In combination with cetuximab for the treatment of adults with KRAS G12C mutated locally advanced or metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy [2]
In combination with Rituximab, this regimen is called R-FCM or R-FMC, or FCM-R, FMC-R. The [R]-FCM regimen contains Rituximab - anti-CD20 monoclonal antibody that can kill both normal and malignant CD20-bearing B cells; Fludarabine - an antimetabolite; Cyclophosphamide - an alkylating antineoplastic agent from the oxazafosforine group;
When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R. The [R]-GemOx regimen consists of: ituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells; citabine - an antimetabolite; aliplatin - a platinum-based alkylating antineoplastic agent. [1] [2]